Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis

C. Lange*, W. A. Alghamdi, M. H. Al-Shaer, S. Brighenti, A. H. Diacon, A. R. DiNardo, H. P. Grobbel, M. I. Gröschel, F. von Groote-Bidlingmaier, M. Hauptmann, J. Heyckendorf, N. Köhler, T. A. Kohl, M. Merker, S. Niemann, C. A. Peloquin, M. Reimann, U. E. Schaible, D. Schaub, V. SchleusenerT. Thye, T. Schön

*Corresponding author for this work
24 Citations (Scopus)


According to the World Health Organization (WHO), tuberculosis is the leading cause of death attributed to a single microbial pathogen worldwide. In addition to the large number of patients affected by tuberculosis, the emergence of Mycobacterium tuberculosis drug-resistance is complicating tuberculosis control in many high-burden countries. During the past 5 years, the global number of patients identified with multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance at least against rifampicin and isoniazid, the two most active drugs in a treatment regimen, has increased by more than 20% annually. Today we experience a historical peak in the number of patients affected by MDR-TB. The management of MDR-TB is characterized by delayed diagnosis, uncertainty of the extent of bacillary drug-resistance, imprecise standardized drug regimens and dosages, very long duration of therapy and high frequency of adverse events which all translate into a poor prognosis for many of the affected patients. Major scientific and technological advances in recent years provide new perspectives through treatment regimens tailor-made to individual needs. Where available, such personalized treatment has major implications on the treatment outcomes of patients with MDR-TB. The challenge now is to bring these adances to those patients that need them most.

Original languageEnglish
JournalJournal of Internal Medicine
Issue number2
Pages (from-to)163-188
Number of pages26
Publication statusPublished - 08.2018

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)


Dive into the research topics of 'Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis'. Together they form a unique fingerprint.

Cite this